HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Sibbel S, Hunt A, Van Wyck DB, et al.

Association Between Antimicrobial Barrier Cap Use and Outcomes Among Hemodialysis Patients Using a Central Venous Catheter

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:53A 2020


Bloodstream infections (BSIs) are a common complication of central venous catheter (CVC) use and contribute to hospitalization, mortality, and high costs of care in patients on hemodialysis (HD). In a prior randomized clinical trial, patients using CVCs with antimicrobial barrier caps (AmBC; ClearGuard® HD, Pursuit Vascular Inc, Maple Grove, MN, USA) had significantly lower catheter-related BSI rates compared to patients using CVCs with the historical standard of care. Based on these findings, AmBCs were introduced in May 2019 as standard of care for CVC patients across a large dialysis organization (LDO). This study assessed changes in clinical outcomes in a real-world HD population following implementation of AmBC use.


Study data were derived from LDO electronic medical records over two 3-month periods: Pre (Jul-Oct 2018) and Post (Jul-Oct 2019) AmBC adoption. Included patients were adults receiving in-center HD treatment 3x/week using a CVC. Crude outcome rates were calculated for individual calendar months and for the pre- and post- periods overall; formal comparisons were made using generalized linear models.


A total of 37,642 patients in the pre-period and 40,498 patients in the post-period met eligibility criteria. Overall BSI rate fell from 0.54/100 CVC days in the pre-period to 0.36/100 CVC days after AmBC implementation. Hospitalization rates were lower during the post-period versus the pre-period overall and within each calendar month; the contribution of underlying temporal changes (eg, background year-over-year change) could not be quantified.


Adoption of AmBCs for use in HD patients using a CVC for vascular access was associated with an early 34% reduction in infections assessed on the basis of positive blood cultures and 0.22 fewer hospital admissions per patient-year.

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.